StockData
Bolt Biotherapeutics, Inc. logo

Bolt Biotherapeutics, Inc. (BOLT) stock

BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/305% below fair value
$5.10−0.55 (-9.73%)

Close on Nov 18, 2026Market cap $9.82MP/E –Yield –

Bolt Biotherapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Bolt Biotherapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$39.92M. For fiscal 2025 it was -$39.92M. The highest annual figure on record is -$39.92M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$39.92M–
FY2024Dec 31, 2024-$61.33M–
FY2023Dec 31, 2023-$69.73M–
FY2022Dec 31, 2022-$78.46M–
FY2021Dec 31, 2021-$59.40M–
FY2020Dec 31, 2020-$50.57M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$3.08M–
Q4 FY2025Dec 31, 2025-$7.16M–
Q3 FY2025Sep 30, 2025-$9.80M–
Q4 FY2024Dec 31, 2024-$14.43M–
Q3 FY2024Sep 30, 2024-$14.01M–
Q2 FY2024Jun 30, 2024-$16.14M–
Q1 FY2024Mar 31, 2024-$16.75M–
Q4 FY2023Dec 31, 2023-$14.27M–
Q3 FY2023Sep 30, 2023-$16.91M–
Q2 FY2023Jun 30, 2023-$15.14M–
Q1 FY2023Mar 31, 2023-$23.40M–
Q4 FY2022Dec 31, 2022-$18.14M–
Q3 FY2022Sep 30, 2022-$14.19M–
Q2 FY2022Jun 30, 2022-$21.22M–
Q1 FY2022Mar 31, 2022-$24.92M–
Q4 FY2021Dec 31, 2021-$18.36M–
Q3 FY2021Sep 30, 2021-$19.74M–
Q2 FY2021Jun 30, 2021-$4.69M–
Q1 FY2021Mar 31, 2021-$16.62M–
Q4 FY2020Dec 31, 2020-$13.79M–
Q3 FY2020Sep 30, 2020-$13.67M–
Q2 FY2020Jun 30, 2020-$13.11M–
Q1 FY2020Mar 31, 2020-$10.01M–

More Bolt Biotherapeutics figures

See a number that looks wrong?